Somatostatin Analogs Market Size

Your Catalyst To a Lucrative Business
Somatostatin Analogs Market Analysis, Size, Share, Growth,
Industry Trends and Forecast to 2024 | Hexa Research
“Somatostatin Analogs Market is expected to witness
a significant growth, pertaining to the rise in the
prevalence of acromegaly and neuroendocrine
tumors coupled with the rising investments in R&D
activities.
25 January 2019, The Global Somatostatin Analogs Market size to reach USD 3.1 billion by 2024, owing to
the rise in the incidence rate of acromegaly and neuroendocrine tumor over the forecast period. Rising
awareness, training and education by Pituitary Association of Australia and UK & Ireland Neuroendocrine
Tumor Society is expected to have positive impact on the market growth in the coming years.
The octreotide type analog brand Sandostatin accounted for more than 67% of the market share in 2016. The
demand for octreotide is expected to show stagnant growth over the forecast period. Owing to the patent
expiration of the drug Sandostatin LAR in 2014 in U.S., which was being marketed by Novartis in North
America, Europe and many other countries across the globe. Rising popularity of Lanreotide brand
Somatuline in the U.S. and Europe is expected to fuel the market growth. Increasing penetration and
popularity of the drug in the market coupled with the rise in the use of Somatuline lanreotide for carcinoid
syndrome and other related disorder is expected to provide lucrative growth opportunity for the
somatostatin analogs in near future.
Browse Details of Report @ https://www.hexaresearch.com/research-report/somatostatin-analogs-market
Follow Us:
Your Catalyst To a Lucrative Business
Lanreotide is a drug used in management and treatment of acromegaly. It is also administered in the
treatment of symptoms caused by carcinoid syndrome. The molecule is long acting somatostatin analog
similar to octreotide. The sequence for lanreotide is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2. The
drug is marketed under the brand name Somatuline and is manufactured by Ipsen.
Neuroendocrine tumor (NET) segment held more than 50% of the market share in 2016. Increasing incidence
rate of neuroendocrine tumors and associated diseases such as carcinoid tumors is the key factor driving the
growth of the market during the forecast period.
North America held more than 45% of market share in 2016. Increasing incidence of acromegaly and
neuroendocrine tumor (NET) coupled with the rise in awareness and accuracy of disease diagnosis in
developed economies is building a positive outlook for the acceptance of somatostatin analogs. Presence of
favorable reimbursement policies, rise in the use of somatostatin analogs for treatment and, growing
research and development activities in the North America is expected to have positive impact on market
growth over the forecast period.
Asia Pacific is expected to exhibit the fastest growth over the forecast period owing to the rise in the
research and development activities in the medical field and the launch of innovative drug formulations are
the main factor driving the growth of somatostatin analogs market over the forecast period.
The global somatostatin analogs industry is consolidated in nature with Novartis AG and IPSEN dominating
market. Companies are adopting new strategies for increasing their R&D activities and introducing new
product such as signifor and signifor LAR (Pasireotide) which are gaining momentum in U. S. and European
market. Competetiors are also entering into new and potential markets where they can expect the product
growth in the near future. For instance, Sun Pharma Advanced Research Company Ltd., had launch
somatostatin analogs product for the treatment of acromegaly in India.
Hexa Research has segmented the global somatostatin analogs market report based on type, indication and
region:
Segmentation by type, 2014 - 2024
• Octreotide
• Lanreotide
• Pasireotide
Segmentation by indication, 2014 - 2024
• Acromegaly
Follow Us:
Your Catalyst To a Lucrative Business
• Neuroendocrine Tumor (NET)
• Others
Segmentation by region, 2014 - 2024
• North America
• U.S.
• Europe
• Germany
• UK
• Asia Pacific
• China
• Japan
• Rest of the World (RoW)
Key players analyzed:
• Novartis AG
• Peptron
• Chiasma, Inc.
• Ipsen Biopharmaceuticals, Inc.
• Sun Pharma Advanced Research Company Ltd.
Browse Related Category Market Reports @ https://www.hexaresearch.com/researchcategory/pharmaceuticals-industry
Follow Us:
Your Catalyst To a Lucrative Business
Table of Content of Somatostatin Analogs Market
Chapter 1. Executive Summary
Chapter 2. Methodology and Scope
2.1. Research methodology
2.2. Assumptions
2.3. List of data sources
Chapter 3. Introduction
3.1. Research scope & market segmentation
Chapter 4. Somatostatin Analogs Market Trends: Drivers & Opportunities
4.1. Key Industry Trends
4.1.1. Raw material trend
4.1.2. Technology trend
4.1.3. Supplier trend
4.1.4. Buyer trend
4.1.5. Regulatory trend
4.2. Market Drivers
4.3. Market Restraints
4.4. Opportunity Assessment
4.5. Raw Material Analysis
4.6. Supply Chain Analysis
4.7. PESTEL Analysis
4.8. Porter's Five Forces analysis
Chapter 5. Somatostatin Analogs Market Trends, By Analogs type
5.1. Global somatostatin analogs market movement, by analogs type, 2016 & 2024
5.1.1. Octreotide
5.1.1.1. Market estimates and forecast, 2015 - 2025 (USD Million)
5.1.2. Lanreotide
5.1.2.1. Market estimates and forecast, 2015 - 2025 (USD Million)
5.1.3. Pasireotide
5.1.3.1. Market estimates and forecast, 2015 - 2025 (USD Million)
Chapter 6. Somatostatin Analogs Market Trends, By Indication
6.1. Global somatostatin analogs market movement, by indication, 2014 & 2024
6.1.1. Acromegaly
6.1.1.1. Market estimates and forecast, 2015 - 2025 (USD Million)
6.1.2. Neuroendocrine Tumor (NET)
Follow Us:
Your Catalyst To a Lucrative Business
6.1.2.1. Market estimates and forecast, 2015 - 2025 (USD Million)
6.1.3. Others
6.1.3.1. Market estimates and forecast, 2015 - 2025 (USD Million)
Chapter 7. Somatostatin Analogs Market Trends, By Region
7.1. Global somatostatin analogs market movement, by region, 2014 & 2024
7.1.1. North America
7.1.1.1. Market estimates and forecast, 2015 - 2025 (USD Million)
7.1.1.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million)
7.1.1.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million)
7.1.2. Europe
7.1.2.1. Market estimates and forecast, 2015 - 2025 (USD Million)
7.1.2.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million)
7.1.2.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million)
7.1.3. Asia-Pacific
7.1.3.1. Market estimates and forecast, 2015 - 2025 (USD Million)
7.1.3.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million)
7.1.3.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million)
7.1.4. Rest of the World (RoW)
7.1.4.1. Market estimates and forecast, 2015 - 2025 (USD Million)
7.1.4.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million)
7.1.4.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million)
Chapter 8. Key Country Markets
8.1. U.S.
8.1.1. Market estimates and forecast, 2015 - 2025 (USD Million)
8.1.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million)
8.1.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million)
8.2. Germany
8.2.1. Market estimates and forecast, 2015 - 2025 (USD Million)
8.2.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million)
8.2.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million)
8.3. UK
8.3.1. Market estimates and forecast, 2015 - 2025 (USD Million)
8.3.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million)
8.3.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million)
8.4. China
8.4.1. Market estimates and forecast, 2015 - 2025 (USD Million)
Follow Us:
Your Catalyst To a Lucrative Business
8.4.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million)
8.4.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million)
8.5. Japan
8.5.1. Market estimates and forecast, 2015 - 2025 (USD Million)
8.5.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million)
8.5.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Market Share Analysis,2016
9.2. Strategic framework
9.3. Company profiles
9.3.1. Novartis AG
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Product Benchmarking
9.3.1.4. SWOT
9.3.1.5. Recent Initiatives
9.3.1.6. Future Outlook and Strategies
9.3.2. Peptron
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Product Benchmarking
9.3.2.4. SWOT
9.3.2.5. Recent Initiatives
9.3.2.6. Future Outlook and Strategies
9.3.3. Chaisma, Inc.
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Product Benchmarking
9.3.3.4. SWOT
9.3.3.5. Recent Initiatives
9.3.3.6. Future Outlook and Strategies
9.3.4. Ipsen Biopharmaceuticals, Inc.
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Product Benchmarking
9.3.4.4. SWOT
Follow Us:
Your Catalyst To a Lucrative Business
9.3.4.5. Recent Initiatives
9.3.4.6. Future Outlook and Strategies
9.3.5. Sun Pharma Advanced Research Company Ltd.
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Product Benchmarking
9.3.5.4. SWOT
9.3.5.5. Recent Initiatives
9.3.5.6. Future Outlook and Strategies
9.3.6. List of other vendors
Follow Us:
Your Catalyst To a Lucrative Business
About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research
and consulting services to a host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients obtain clarity about their business
environment and enable them to undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - https://www.hexaresearch.com
Follow Us:

The global somatostatin analogs market size to reach USD 3.1 billion by 2024

Download Report